Evaluation of comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators in the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of RCTs

BMC Pulm Med. 2024 Dec 18;24(1):609. doi: 10.1186/s12890-024-03445-4.

Abstract

Background: UMEC/VI administered via a combination inhaler is associated with a clinically significant improvement in lung function and health-related quality of life in patients with mild-to-moderate COPD. However, their efficacy compared to other bronchodilator mono or dual therapies still remains unclear.

Objective: The objective of this research was to evaluate the therapeutic efficacy of UMEC/VI dual and UMEC/VI/FF triple therapies versus alternative bronchodilator regimens in COPD patients.

Methods: A systematic search was conducted using four electronic databases (PubMed, EMBASE, Scopus, and Cochrane Library) to select publications published in peer-reviewed journals written in English. The odds ratio (OR) and risk ratio (RR) was calculated, along with their 95% confidence intervals. We assessed heterogeneity using Cochrane Q and I [2] statistics and the appropriate p-value. The analysis used RevMan 5.4.

Results: The current meta-analysis includes 31,814 COPD patients from 17 RCTs. The meta-analysis results demonstrate that the combination of LABA and LAMA provides additive bronchodilation and improved lung function in COPD patients. We found that UMEC/VI dual therapy significantly improved FEV1 (OR 1.98 [95% CI 1.70-2.30]), TDI values (OR 1.97 [95% CI 1.72-2.26]), and reduced SGRQ total scores (OR 1.99 [95% CI 1.71-2.32]), with fewer drug-related adverse events (RR 0.58 [95% CI 0.53-0.64]). Similarly, UMEC/VI/FF triple therapy also showed similar benefits, with significant improvements in FEV1 (OR 1.93 [95% CI 1.73-2.15]), TDI values (OR 2.37 [95% CI 2.15-2.61]), and reduced SGRQ total scores (OR 1.83 [95% CI 1.63-2.05]), and fewer drug-related adverse events (RR 0.53 [95% CI 0.49-0.58]).

Conclusion: This systematic review and meta-analysis concludes that UMEC and VI combinations are an efficacious treatment option for symptomatic COPD patients.

Keywords: Chronic obstructive pulmonary disease (COPD), Bronchodilators; Fluticasone furoate (FF); Indacaterol/glycopyrrolate (IND/GLY); Long acting beta2-agonists (LABA); Long-acting muscarinic antagonists (LAMA); Salmeterol/Fluticasone propionate (SAL/FP); Tiotropium/olodaterol (TIO/OLO); Umeclidinium/Vilanterol (UMEC/VI).

Publication types

  • Systematic Review
  • Meta-Analysis
  • Review
  • Comparative Study

MeSH terms

  • Administration, Inhalation
  • Benzyl Alcohols* / administration & dosage
  • Benzyl Alcohols* / therapeutic use
  • Bronchodilator Agents* / administration & dosage
  • Bronchodilator Agents* / therapeutic use
  • Chlorobenzenes* / administration & dosage
  • Chlorobenzenes* / adverse effects
  • Chlorobenzenes* / therapeutic use
  • Drug Combinations
  • Forced Expiratory Volume / drug effects
  • Humans
  • Pulmonary Disease, Chronic Obstructive* / drug therapy
  • Pulmonary Disease, Chronic Obstructive* / physiopathology
  • Quality of Life
  • Quinuclidines* / administration & dosage
  • Quinuclidines* / adverse effects
  • Quinuclidines* / therapeutic use
  • Randomized Controlled Trials as Topic*
  • Treatment Outcome

Substances

  • Bronchodilator Agents
  • GSK573719
  • vilanterol
  • Quinuclidines
  • Benzyl Alcohols
  • Chlorobenzenes
  • Drug Combinations